RB1 and breast cancer: The Rb loss-of-function signature (RBsig) derived by Malorni et al. has been shown to discriminate palbociclib-resistant versus sensitive breast cancer cell lines [23] and to be enriched in palbociclib-resistant tumours of patients treated in the NeoPalAna trial [24].